Australia’s active vaccine safety system

AusVaxSafety is conducting active safety surveillance of Beyfortus (nirsevimab) – a new long-acting injectable monoclonal antibody product used for the prevention of severe respiratory syncytial virus (RSV) disease in infants – at participating sites in New South Wales and Queensland to ensure its ongoing safety.

In Australia, nirsevimab is currently only available to infants and young children through state-managed programs in New South Wales, Queensland and Western Australia.

Safety data are gathered via surveys sent to recipients in the days following nirsevimab administration.

The Western Australia RSV immunisation program also includes active safety surveillance, with reports published through Government of Western Australia Department of Health channels.

AusVaxSafety nirsevimab safety data from New South Wales and Queensland will be published on this page once enough data are collected to enable meaningful analysis.